ArticleFrontiers in immunology2026
Emapunil attenuates ulcerative colitis by suppressing Z-DNA binding protein 1 driven pyroptosis and pro-inflammatory polarization in macrophages.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The pathogenesis of ulcerative colitis (UC) remains incompletely understood, and effective therapeutic targets are still lacking in clinical practice. Macrophage pyroptosis and polarization imbalance are core events in UC progression. As a key upstream regulator of pyroptosis, the role of Z-DNA binding protein 1 (ZBP1) in UC-associated macrophages has not been systematically elucidated. Our previous study demonstrated that Emapunil could suppress macrophage inflammation and downregulate ZBP1 expression, suggesting its potential as a candidate agent for UC treatment. Methods: Immunofluorescence was used to detect the expression and localization of ZBP1 in colorectal tissues from UC patients and DSS-induced colitis mice. ZBP1 overexpression, knockdown, and Emapunil intervention were performed in macrophages to analyze their effects on pyroptosis, polarization, NF-κB pathway, and intestinal barrier function. The therapeutic effect and mechanism of Emapunil on UC were verified via Results: ZBP1 was significantly upregulated in colorectal macrophages from UC patients. Overexpression of ZBP1 induced macrophage pyroptosis and M1 polarization, activated the NF-κB pathway and impaired intestinal barrier integrity, whereas ZBP1 knockdown markedly reversed these effects. By targeting TSPO, Emapunil effectively suppressed macrophage pyroptosis and inflammatory polarization via downregulating ZBP1, alleviated DSS-induced colonic injury, and preserved intestinal barrier function in mice. Conclusion: ZBP1 aggravates intestinal inflammation and barrier damage by driving macrophage pyroptosis and pro-inflammatory polarization, representing a novel key molecule regulating abnormal macrophage activation in UC. By targeting TSPO, Emapunil exerts anti-UC effects through downregulation of ZBP1, thereby providing a novel mechanism and a potential therapeutic strategy for the clinical management of ulcerative colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.